Prosecution Insights
Prosecution Insights
16 pending office actions • 12 clients • 16 examiners • 12 art units • 0 of 16 (0%) have an AI response strategy ready • 18 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 5 (31%) |
| §102 only | 1 (6%) |
| §112 only | 2 (12%) |
| Double-patenting + other | 2 (12%) |
| Multi-statute (no §101) | 6 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GULLEDGE, BRIAN M | 1 | 55.6% | +26.3% |
| RAHMANI, NILOOFAR | 1 | 77.5% | -3.1% |
| ALLEN, MARIANNE P | 1 | 60.1% | +18.3% |
| CHESTNUT, BARRY A | 1 | 73.4% | +6.3% |
| MERTZ, PREMA MARIA | 1 | 71.6% | +35.6% |
| DONOGHUE, BRITTNEY ERIN | 1 | 58.6% | +48.8% |
| HIRAKIS, SOPHIA P | 1 | 52.2% | +73.3% |
| AUDET, MAURY A | 1 | 50.0% | +23.8% |
| JUEDES, AMY E | 1 | 45.0% | +41.4% |
| ESPINOSA, CLAUDIA EDILMA | 1 | 52.9% | +56.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17978647 | ANTIBIOTIC COMBINATION THERAPIES | ESPINOSA, CLAUDIA EDILMA | 31d overdue |
| 17613898 | GLUCONATE DEHYDRATASE ENZYMES AND RECOMBINANT CELLS | IANNUZO, NATALIE NMN | 24d overdue |
| 17620987 | DOSING REGIMEN AND COMBINATION THERAPIES FOR MULTISPECIFIC ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN | NICKOL, GARY B | 15d overdue |
| 18615334 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF HYPERCYTOKINEMIA AND SEVERE INFLUENZA | RAHMANI, NILOOFAR | — |
| 18251443 | METHODS FOR TREATMENT OF CANCER AND PHAGOCYTOSIS-DEFICIENCY RELATED DISEASES | HIRAKIS, SOPHIA P | — |
| 17612204 | TRACELESS LINKERS AND PROTEIN-CONJUGATES THEREOF | STONEBRAKER, ALYSSA RAE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17978647 | ANTIBIOTIC COMBINATION THERAPIES | ESPINOSA, CLAUDIA EDILMA | 31d overdue |
| 18700066 | NANOPARTICULATE FORMULATION | GULLEDGE, BRIAN M | — |
| 18580810 | IL12 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | ALLEN, MARIANNE P | — |
| 18328327 | INTERLEUKIN-2 PROPROTEINS AND USES THEREOF | MERTZ, PREMA MARIA | — |
| 18324380 | INTERLEUKIN-2 PROPROTEINS AND USES THEREOF | DONOGHUE, BRITTNEY ERIN | — |
| 18251443 | METHODS FOR TREATMENT OF CANCER AND PHAGOCYTOSIS-DEFICIENCY RELATED DISEASES | HIRAKIS, SOPHIA P | — |
| 18247465 | METHODS FOR TREATING EYE DISEASES USING LIPID BINDING PROTEIN-BASED COMPLEXES | AUDET, MAURY A | — |
| 18003279 | IMMUNOTHERAPY | JUEDES, AMY E | — |
| Client (Assignee) | Pending OAs |
|---|---|
| REGENERON PHARMACEUTICALS, INC. | 4 |
| NEOGAP THERAPEUTICS AB | 2 |
| NewImmune II, LLC | 1 |
| Poolbeg Pharma (UK) Limited | 1 |
| DYNO THERAPEUTICS, INC. | 1 |
| Rdiscovery, LLC | 1 |
| Abionyx Pharma | 1 |
| Bioversys | 1 |
| Novartis | 1 |
| Synthis Therapeutics, Inc. | 1 |
| University of Cambridge | 1 |
| BP plc | 1 |
| Art Unit | Apps |
|---|---|
| 1654 | 2 |
| 1644 | 2 |
| 1642 | 2 |
| 1699 | 1 |
| 1691 | 1 |
| 1672 | 1 |
| 1674 | 1 |
| 1675 | 1 |
| 1623 | 1 |
| 1643 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18700066 | NANOPARTICULATE FORMULATION | Newimmune Ii, LLC | GULLEDGE, BRIAN M | 1699 | §103 | Final Rejection | — | Pending | Apr 10, 2024 |
| 18615334 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF HYPERCYTOKINEMIA AND SEVERE INFLUENZA | Poolbeg Pharma (Uk) Limited | RAHMANI, NILOOFAR | 1691 | §102§112 | Non-Final OA | — | Pending | Mar 25, 2024 |
| 18580810 | IL12 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Regeneron Pharmaceuticals, Inc. | ALLEN, MARIANNE P | §112 | Non-Final OA | — | Pending | Jan 19, 2024 | |
| 18573582 | CAPSID VARIANTS AND METHODS OF USING THE SAME | Dyno Therapeutics, Inc. | CHESTNUT, BARRY A | 1672 | §102 | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18328327 | INTERLEUKIN-2 PROPROTEINS AND USES THEREOF | Regeneron Pharmaceuticals, Inc. | MERTZ, PREMA MARIA | 1674 | §112 | Non-Final OA | — | Pending | Jun 02, 2023 |
| 18324380 | INTERLEUKIN-2 PROPROTEINS AND USES THEREOF | Regeneron Pharmaceuticals, Inc. | DONOGHUE, BRITTNEY ERIN | 1675 | §103 | Non-Final OA | — | Pending | May 26, 2023 |
| 18251443 | METHODS FOR TREATMENT OF CANCER AND PHAGOCYTOSIS-DEFICIENCY RELATED DISEASES | Rdiscovery, LLC | HIRAKIS, SOPHIA P | 1623 | §103§112 | Non-Final OA | — | Pending | May 02, 2023 |
| 18247465 | METHODS FOR TREATING EYE DISEASES USING LIPID BINDING PROTEIN-BASED COMPLEXES | Abionyx Pharma SA | AUDET, MAURY A | 1654 | §103 | Final Rejection | — | Pending | Mar 31, 2023 |
| 18003279 | IMMUNOTHERAPY | Neogap Therapeutics AB | JUEDES, AMY E | 1644 | §103DP | Final Rejection | — | Pending | Dec 23, 2022 |
| 17978647 | ANTIBIOTIC COMBINATION THERAPIES | BIOVERSYS AG | ESPINOSA, CLAUDIA EDILMA | 1654 | §103§112Other | Final Rejection | 31d overdue | Pending | Nov 01, 2022 |
| 17620987 | DOSING REGIMEN AND COMBINATION THERAPIES FOR MULTISPECIFIC ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN | Novartis AG | NICKOL, GARY B | 1643 | §102§112Other | Non-Final OA | 15d overdue | Pending | Dec 20, 2021 |
| 17620222 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | Synthis Therapeutics, Inc. | BUTTICE, AUDREY L | 1647 | §103DP | Non-Final OA | — | Pending | Dec 17, 2021 |
| 17616246 | BREAST CANCER DETECTION METHODS | Cambridge Enterprise Limited | SULLIVAN, DENNIS JOHN | 1642 | §103 | Non-Final OA | 5d overdue | Pending | Dec 03, 2021 |
| 17613898 | GLUCONATE DEHYDRATASE ENZYMES AND RECOMBINANT CELLS | BP CORPORATION NORTH AMERICA INC. | IANNUZO, NATALIE NMN | 1653 | §103§112 | Final Rejection | 24d overdue | Pending | Nov 23, 2021 |
| 17612204 | TRACELESS LINKERS AND PROTEIN-CONJUGATES THEREOF | Regeneron Pharmaceuticals, Inc. | STONEBRAKER, ALYSSA RAE | 1642 | §103§112 | Final Rejection | — | Pending | Nov 17, 2021 |
| 17417601 | PHAGOCYTISABLE PARTICLE FOR USE IN THE TREATMENT OR PROPHYLAXIS OF CANCER | Neogap Therapeutics AB | JOHANSEN, PETER N. | 1644 | §103Other | Final Rejection | 17d overdue | Pending | Jun 23, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial